Xeris Pharmaceuticals has entered into a Feasibility Evaluation Agreement with Asahi Kasei Pharma Corporation (“AKP”).  AKP is a research-based pharmaceutical company specializing in the therapeutic areas of pain management, musculoskeletal disorders, and critical care medicine.  AKP is a wholly-owned subsidiary of Asahi Kasei Corporation, which is a shareholder of Xeris.    The goal of the feasibility evaluation is to understand if a particular therapeutic from AKP’s product portfolio c...